# Betty Y S Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/904857/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 59 papers | 9,109 citations | 117619 34 h-index | 128286 60 g-index |
| 62 all docs | 62 docs citations | 62 times ranked | 15141 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Challenges and opportunities of nanotechnology in cancer immunotherapy. , 2022, , 197-239. | | 1 |
| 2 | Strategies of Perturbing Ion Homeostasis for Cancer Therapy. Advanced Therapeutics, 2022, 5, 2100189. | 3.2 | 3 |
| 3 | Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nature Communications, 2022, 13, 767. | 12.8 | 128 |
| 4 | Cancer nanomedicines for enhanced immunotherapy. , 2022, , . | | 0 |
| 5 | Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors. Cancer Research Communications, 2022, 2, 402-416. | 1.7 | 2 |
| 6 | Cancer immunotherapy based on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nature Nanotechnology, 2022, 17, 891-899. | 31.5 | 74 |
| 7 | Immune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight, 2022, 7, . | 5.0 | 10 |
| 8 | Harnessing cGASâ€STING Pathway for Cancer Immunotherapy: From Bench to Clinic. Advanced Therapeutics, 2022, 5, . | 3.2 | 2 |
| 9 | Considerations for designing preclinical cancer immune nanomedicine studies. Nature Nanotechnology, 2021, 16, 6-15. | 31.5 | 77 |
| 10 | Vascular ApoE4 Impairs Behavior by Modulating Gliovascular Function. Neuron, 2021, 109, 438-447.e6. | 8.1 | 42 |
| 11 | Spatiotemporal Immunomodulation Using Biomimetic Scaffold Promotes Endochondral Ossificationâ€Mediated Bone Healing. Advanced Science, 2021, 8, e2100143. | 11.2 | 33 |
| 12 | Self-Assembled pH-Sensitive Polymeric Nanoparticles for the Inflammation-Targeted Delivery of Cu/Zn-Superoxide Dismutase. ACS Applied Materials & Interfaces, 2021, 13, 18152-18164. | 8.0 | 14 |
| 13 | Harnessing Innate Immunity Using Biomaterials for Cancer Immunotherapy. Advanced Materials, 2021, 33, e2007576. | 21.0 | 42 |
| 14 | Advanced Immunotherapy Approaches for Glioblastoma. Advanced Therapeutics, 2021, 4, 2100046. | 3.2 | 8 |
| 15 | Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clinical Cancer Research, 2020, 26, 1712-1724. | 7.0 | 76 |
| 16 | Nanotechnology platforms for cancer immunotherapy. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1590. | 6.1 | 82 |
| 17 | Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nature Biomedical Engineering, 2020, 4, 69-83. | 22.5 | 415 |
| 18 | The role of radiation therapy in treatment of adults with newly diagnosed glioblastoma multiforme: a systematic review and evidence-based clinical practice guideline update. Journal of Neuro-Oncology, 2020, 150, 215-267. | 2.9 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nature Communications, 2020, 11, 1508. | 12.8 | 138 |
| 20 | Extracellular Vesicles: An Emerging Nanoplatform for Cancer Therapy. Frontiers in Oncology, 2020, 10, 606906. | 2.8 | 36 |
| 21 | Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. JAMA Network Open, 2020, 3, e2028627. | 5.9 | 22 |
| 22 | Tumor Vasculatures: A New Target for Cancer Immunotherapy. Trends in Pharmacological Sciences, 2019, 40, 613-623. | 8.7 | 79 |
| 23 | On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology, 2019, 14, 629-635. | 31.5 | 149 |
| 24 | Folate Receptor-Targeted Albumin Nanoparticles Based on Microfluidic Technology to Deliver Cabazitaxel. Cancers, 2019, 11, 1571. | 3.7 | 34 |
| 25 | Membrane TLR9 Positive Neutrophil Mediated MPLA Protects Against Fatal Bacterial Sepsis. Theranostics, 2019, 9, 6269-6283. | 10.0 | 22 |
| 26 | Phagocytosis checkpoints as new targets for cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 568-586. | 28.4 | 557 |
| 27 | Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery. Advanced Science, 2019, 6, 1802070. | 11.2 | 82 |
| 28 | Visualization of Hepatocellular Regeneration in Mice After Partial Hepatectomy. Journal of Surgical Research, 2019, 235, 494-500. | 1.6 | 6 |
| 29 | The Reciprocity between Radiotherapy and Cancer Immunotherapy. Clinical Cancer Research, 2019, 25, 1709-1717. | 7.0 | 95 |
| 30 | Improving immuneâ€“vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 195-203. | 22.7 | 340 |
| 31 | Study of Osteocyte Behavior by High-Resolution Intravital Imaging Following Photo-Induced Ischemia. Molecules, 2018, 23, 2874. | 3.8 | 2 |
| 32 | How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nature Biomedical Engineering, 2018, 2, 797-809. | 22.5 | 99 |
| 33 | Immunomodulating Nanomedicine for Cancer Therapy. Nano Letters, 2018, 18, 6655-6659. | 9.1 | 121 |
| 34 | Perspectives of Nanotechnology in the Management of Gliomas. Progress in Neurological Surgery, 2018, 32, 196-210. | 1.3 | 4 |
| 35 | Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. Journal of Clinical Investigation, 2018, 128, 2104-2115. | 8.2 | 152 |
| 36 | Designing nanomedicine for immuno-oncology. Nature Biomedical Engineering, 2017, 1, . | 22.5 | 178 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotechnology, 2017, 12, 763-769. | 31.5 | 136 |
| 38 | Lessons from immuno-oncology: a new era for cancer nanomedicine?. Nature Reviews Drug Discovery, 2017, 16, 369-370. | 46.4 | 37 |
| 39 | Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology, 2017, 125, 80-88. | 0.6 | 58 |
| 40 | S100A4 Is a Biomarker and Regulator of Glioma Stem Cells That Is Critical for Mesenchymal Transition in Glioblastoma. Cancer Research, 2017, 77, 5360-5373. | 0.9 | 78 |
| 41 | Breaking Down the Barriers to Precision Cancer Nanomedicine. Trends in Biotechnology, 2017, 35, 159-171. | 9.3 | 254 |
| 42 | The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget, 2016, 7, 24848-24859. | 1.8 | 40 |
| 43 | Prognostic value of p16 expression in Epsteinâ€Barr virusâ€“positive nasopharyngeal carcinomas. Head and Neck, 2016, 38, E1459-66. | 2.0 | 28 |
| 44 | Immune Priming of the Tumor Microenvironment by Radiation. Trends in Cancer, 2016, 2, 638-645. | 7.4 | 120 |
| 45 | The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. Practical Radiation Oncology, 2016, 6, 241-247. | 2.1 | 41 |
| 46 | Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Scientific Reports, 2016, 6, 26269. | 3.3 | 167 |
| 47 | Cerebral Venous Thrombosis Associated with Intracranial Hemorrhage and Timing of Anticoagulation after Hemicraniectomy. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 2312-2316. | 1.6 | 23 |
| 48 | Non-contiguous meningeal metastases of olfactory neuroblastoma. Journal of Neuro-Oncology, 2016, 126, 201-203. | 2.9 | 13 |
| 49 | Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget, 2016, 7, 32156-32171. | 1.8 | 14 |
| 50 | Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Research and Treatment, 2015, 150, 439-445. | 2.5 | 30 |
| 51 | Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano, 2015, 9, 8689-8696. | 14.6 | 134 |
| 52 | Diagnostic discrepancies in malignant astrocytoma due to limited small pathological tumor sample can be overcome by IDH1 testing. Journal of Neuro-Oncology, 2014, 118, 405-412. | 2.9 | 28 |
| 53 | Pazopanib therapy for cerebellar hemangioblastomas in von Hippelâ€“Lindau disease. Targeted Oncology, 2012, 7, 145-149. | 3.6 | 34 |
| 54 | Nanomedicine. New England Journal of Medicine, 2010, 363, 2434-2443. | 27.0 | 987 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Nanoparticle-mediated cellular response is size-dependent. Nature Nanotechnology, 2008, 3, 145-150. | 31.5 | 2,452 |
| 56 | Biodegradable Quantum Dot Nanocomposites Enable Live Cell Labeling and Imaging of Cytoplasmic Targets. Nano Letters, 2008, 8, 3887-3892. | 9.1 | 116 |
| 57 | Assessing Near-Infrared Quantum Dots for Deep Tissue, Organ, and Animal Imaging Applications. Journal of the Association for Laboratory Automation, 2008, 13, 6-12. | 2.8 | 30 |
| 58 | Advances and challenges of nanotechnology-based drug delivery systems. Expert Opinion on Drug Delivery, 2007, 4, 621-633. | 5.0 | 108 |
| 59 | Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature, 2002, 417, 74-78. | 27.8 | 1,023 |